CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 112 enrolled
Drug / intervention
Fixed-Combination Bimatoprost/Brimonidine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01863953
NCT01863953Phase 2Completed
CompareCT.gov

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

Allergan·interventional·Posted May 29, 2013·Updated Jan 26, 2015

In Brief

A Phase 2 clinical trial evaluating Fixed-Combination Bimatoprost/Brimonidine, Bimatoprost Ophthalmic Solution 0.01%, and 2 other interventions for Glaucoma and Ocular Hypertension. Completed, enrolled 112 participants across 1 site.

Detailed Summary

This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine compared with LUMIGAN® and ALPHAGAN® in patients with chronic glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 29, 2013
Enrollment StartJun 1, 2013
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.1 years ago

Interventions

Fixed-Combination Bimatoprost/Brimonidinedrug

One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.

Bimatoprost Ophthalmic Solution 0.01%drug

One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.

Vehicle Ophthalmic Solutiondrug

One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.

Brimonidine Tartrate Ophthalmic Solution 0.2%drug

One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.